DNDi, Abbott (ABT) Enter Tropical Disease Research Agreement

The Drugs for Neglected Diseases initiative (DNDi) and Abbott (NYSE: ABT) have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Abbott settles preterm formula NEC lawsuits for $670 million
• Virtus Investment Partners names Jack Boyce to its board
• Firm Capital Apartment REIT posts Q2 loss, plans name change